Literature DB >> 31074651

T-cell recruitment to the heart: friendly guests or unwelcome visitors?

Robert M Blanton1, Francisco J Carrillo-Salinas2, Pilar Alcaide2.   

Abstract

Myocardial inflammation can lead to lethal acute or chronic heart failure (HF). T lymphocytes (T cells), have been reported in the inflamed heart in different etiologies of HF, and more recent studies support that different T-cell subsets play distinct roles in the heart depending on the inflammation-triggering event. T cells follow sequential steps to extravasate into tissues, but their specific recruitment to the heart is determined by several factors. These include differences in T-cell responsiveness to specific chemokines in the heart environment, as well as differences in the expression of adhesion molecules in response to distinct stimuli, which regulate T-cell recruitment to the heart and have consequences in cardiac remodeling and function. This review focuses on recent advances in our understanding of the role T cells play in the heart, including its critical role for host defense to virus and myocardial healing postischemia, and its pathogenic role in chronic ischemic and nonischemic HF. We discuss a variety of mechanisms that contribute to the inflammatory damage to the heart, as well as regulatory mechanisms that limit the magnitude of T-cell-mediated inflammation. We also highlight areas in which further research is needed to understand the role T cells play in the heart and distinguish the findings reported in experimental animal models and how they may translate to clinical observations in the human heart.

Entities:  

Keywords:  T cells; heart failure

Mesh:

Substances:

Year:  2019        PMID: 31074651      PMCID: PMC6692732          DOI: 10.1152/ajpheart.00028.2019

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  107 in total

Review 1.  Current concepts in lymphocyte homing and recirculation.

Authors:  G Wiedle; D Dunon; B A Imhof
Journal:  Crit Rev Clin Lab Sci       Date:  2001-02       Impact factor: 6.250

2.  IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart.

Authors:  DeLisa Fairweather; Sylvia Frisancho-Kiss; Susy A Yusung; Masheka A Barrett; Sarah E Davis; Ronelle A Steele; Shannon J L Gatewood; Noel R Rose
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

3.  Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction.

Authors:  U Eriksson; M O Kurrer; R Bingisser; H P Eugster; P Saremaslani; F Follath; S Marsch; U Widmer
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

4.  Prevalence of autoantibodies against contractile proteins in coronary artery disease and their clinical implications.

Authors:  G Dangas; M M Konstadoulakis; S E Epstein; C I Stefanadis; G D Kymionis; M G Toutouza; C Liakos; A Sadaniantz; A M Cohen; J H Chesebro; P K Toutouzas
Journal:  Am J Cardiol       Date:  2000-04-01       Impact factor: 2.778

5.  Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart.

Authors:  DeLisa Fairweather; Sylvia Frisancho-Kiss; Susy A Yusung; Masheka A Barrett; Sarah E Davis; Shannon J L Gatewood; Dolores B Njoku; Noel R Rose
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

Authors:  Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

7.  Widespread myocardial inflammation and infarct-related artery patency.

Authors:  Antonio Abbate; Elena Bonanno; Alessandro Mauriello; Rossana Bussani; Giuseppe G L Biondi-Zoccai; Giovanna Liuzzo; Antonio Maria Leone; Furio Silvestri; Aldo Dobrina; Feliciano Baldi; Franco Pandolfi; Luigi M Biasucci; Alfonso Baldi; Luigi G Spagnoli; Filippo Crea
Journal:  Circulation       Date:  2004-06-21       Impact factor: 29.690

8.  Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.

Authors:  Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

9.  Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure.

Authors:  Arne Yndestad; Are M Holm; Fredrik Müller; Svein Simonsen; Stig S Frøland; Lars Gullestad; Pål Aukrust
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

10.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

Authors:  Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven Snapinn; Katherine E Harris; Peter Aurup; Jonathan M Edelman; Hans Wedel; Lars H Lindholm; Björn Dahlöf
Journal:  JAMA       Date:  2004-11-17       Impact factor: 56.272

View more
  28 in total

1.  CARdiac Immunotherapy: T Cells Engineered to Treat the Fibrotic Heart.

Authors:  Ronald J Vagnozzi; Anne Katrine Z Johansen; Jeffery D Molkentin
Journal:  Mol Ther       Date:  2019-10-01       Impact factor: 11.454

2.  T-cell regulation of fibroblasts and cardiac fibrosis.

Authors:  Amy D Bradshaw; Kristine Y DeLeon-Pennell
Journal:  Matrix Biol       Date:  2020-05-11       Impact factor: 11.583

3.  Pressure overload generates a cardiac-specific profile of inflammatory mediators.

Authors:  Matthew O'Brien; Catalin F Baicu; An O Van Laer; Yuhua Zhang; Lindsey T McDonald; Amanda C LaRue; Michael R Zile; Amy D Bradshaw
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-06-26       Impact factor: 4.733

Review 4.  A cardioimmunologist's toolkit: genetic tools to dissect immune cells in cardiac disease.

Authors:  Anthony Wong; Homaira Hamidzada; Slava Epelman
Journal:  Nat Rev Cardiol       Date:  2022-05-06       Impact factor: 32.419

5.  The contribution of the cardiomyocyte to tissue inflammation in cardiomyopathies.

Authors:  Van Kim Ninh; Joan Heller Brown
Journal:  Curr Opin Physiol       Date:  2020-10-14

6.  Molecular Mechanisms behind Persistent Presence of Parvovirus B19 in Human Dilated Myocardium.

Authors:  Daiva Bironaitė; Ieva Kažukauskienė; Julius Bogomolovas; Dainius Daunoravičius; Artūras Jakubauskas; Dalius Vitkus; Edvardas Žurauskas; Kęstutis Ručinskas; Siegfried Labeit; Virginija Grabauskiene
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 7.  Adaptive immunity-driven inflammation and cardiovascular disease.

Authors:  Daria V Ilatovskaya; Ganesh V Halade; Kristine Y DeLeon-Pennell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-11-08       Impact factor: 4.733

Review 8.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

Review 9.  Fibroblast contributions to ischemic cardiac remodeling.

Authors:  Ryan M Burke; Kimberly N Burgos Villar; Eric M Small
Journal:  Cell Signal       Date:  2020-11-02       Impact factor: 4.315

10.  Chemokines in cardiac fibrosis.

Authors:  Ruoshui Li; Nikolaos G Frangogiannis
Journal:  Curr Opin Physiol       Date:  2020-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.